Cancers, Vol. 15, Pages 1983: Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

Cancers, Vol. 15, Pages 1983: Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience Cancers doi: 10.3390/cancers15071983 Authors: Adriana Trabal Amber Gibson Jiasen He David McCall Michael Roth Cesar Nuñez Miriam Garcia Meredith Buzbee Laurie Toepfer Aram Bidikian Naval Daver Tapan Kadia Nicholas J. Short Ghayas C. Issa Farhad Ravandi Courtney D. DiNardo Guillermo Montalban Bravo Sofia Garces Andrea Marcogliese Hana Paek Zoann Dreyer Julienne Brackett Michele Redell Joanna Yi Guillermo Garcia-Manero Marina Konopleva Alexandra Stevens Branko Cuglievan The BCL-2 inhibitor venetoclax improves survival for adult patients with acute myeloid leukemia (AML) in combination with lower-intensity therapies, but its benefit in pediatric patients with AML remains unclear. We retrospectively reviewed two Texas Medical Center institutions’ experience with venetoclax in 43 pediatric patients with AML; median age 17 years (range, 0.6–21). This population was highly refractory; 44% of patients (n = 19) had ≥3 prior lines of therapy, 37% (n = 16) had received a prior bone marrow transplant, and 81% (n = 35) had unfavorable genetics (KMT2A (n = 17), WT1 (n = 13), FLT3-ITD (n = 10), monosomy 7 (n = 5), TP53 (n = 3), Inv(3) (n = 3), IDH1/2 (n = 2), monosomy 5 (n = 1), NUP98 (n = 1) and ASXL1 (n = 1). The majority (86%) received venetoclax with a hypomethyla...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research